Craig-Hallum Maintains Inotiv(NOTV.US) With Buy Rating
Lake Street Maintains Inotiv(NOTV.US) With Buy Rating, Maintains Target Price $6
Craig-Hallum Maintains Inotiv(NOTV.US) With Buy Rating
Lake Street Maintains Inotiv(NOTV.US) With Buy Rating, Maintains Target Price $6
Analysts Offer Insights on Healthcare Companies: Inotiv (NOTV), Ascendis Pharma (ASND) and Champions Oncology (CSBR)
Craig-Hallum Maintains Inotiv(NOTV.US) With Buy Rating, Announces Target Price $10
Lake Street Maintains Inotiv(NOTV.US) With Buy Rating, Raises Target Price to $6
Craig-Hallum Maintains Inotiv(NOTV.US) With Buy Rating
Craig-Hallum Maintains Inotiv(NOTV.US) With Buy Rating
Craig-Hallum Maintains Inotiv(NOTV.US) With Buy Rating
Inotiv Analyst Ratings
Lake Street Upgrades Inotiv(NOTV.US) to Buy Rating, Raises Target Price to $4
Analysts' Top Healthcare Picks: Inotiv (NOTV), Ironwood Pharma (IRWD)
Inotiv Upgraded to Buy From Hold at Lake Street
Lake Street Maintains Inotiv(NOTV.US) With Hold Rating, Maintains Target Price $2
Lake Street Maintains Inotiv(NOTV.US) With Hold Rating, Maintains Target Price $2
Lake Street Sticks to Their Hold Rating for Inotiv (NOTV)
Inotiv (NOTV) Gets a Hold From Lake Street
Craig-Hallum Maintains Inotiv(NOTV.US) With Buy Rating
Craig-Hallum Maintains Inotiv(NOTV.US) With Buy Rating